经靶动脉灌注银杏叶提取物对重症血栓闭塞性脉管炎患者疼痛影响的观察

Study on the effect of target peripheral arterial infusion of Ginkgo biloba extract in patients with thrombotic obliterans of lower extremities on pain

目的探讨经靶动脉灌注银杏叶提取物(GBE)注射液对重症血栓闭塞性脉管炎(TAO)患者疼痛的影响。方法选取本院2015年6月至2018年7月重症TAO患者164例,接受保守治疗者68例设为对照组,经靶动脉灌注GBE注射液治疗96例为观察组。给予相同的疼痛护理,分别在治疗前、治疗后第3天、30天、90天行疼痛评估;分别在治疗前、治疗后第30天、90天,行生活自理能力评估。结果 2组治疗前疼痛评分差异无统计学意义(P>0.05);治疗后第3天、30天、90天2组疼痛评分纵向比较差异有统计学意义(P<0.001)。观察组疼痛评分随时间变化呈明显下降趋势;对照组在治疗后疼痛评分总体有所下降,但在治疗后3天开始疼痛评分呈上升趋势。2组患者生活自理能力评分比较差异有统计学意义(P<0.001)。结论经靶动脉灌注GBE注射液对减轻重症TAO患者疼痛效果显著,患者活动能力提高,自理能力得到提高,总体生活质量提高,值得临床推广使用。

Objective To investigate the effect of perfusion of Ginkgo biloba extract(GBE)on the pain of patients with severe thromboangiitis obliterans(TAO).Methods From June 2015 to July 2018,164 patients with severe TAO were enrolled in our hospital.68 patients underwent conservative treatment as the control group.96 patients were treated with target arterial infusion of GBE injection.The same pain care was given,and pain assessment was performed before treatment and on the 3rd,30th,and 90th day after treatment;the patient's self-care ability assessment was performed before treatment and on the 30th and 90th days after treatment.Results There was no significant difference in the pain scores between the two groups before treatment(P>0.05).There was a statistically significant difference in pain scores between the 2nd,30th,and 90th day after treatment(P<0.001).The pain score of the observation group showed a significant downward trend with time;the pain score of the control group decreased after treatment,but the pain score began to increase 3 days after treatment.There was a statistically significant difference in the scores of self-care ability between the two groups(P<0.001).Conclusion Perfusion of GBE injection through the target artery can significantly reduce the pain of patients with severe TAO.The patient's activity ability is improved,the self-care ability is improved,and the overall quality of life is improved.It is worthy of clinical promotion.